Sputum Microbiome Composition in Patients with Squamous Cell Lung Carcinoma
Abstract
:1. Introduction
2. Methods
2.1. Cohort Information
2.2. Sample Collection, Process, and Storage
2.3. DNA Extraction, 16S rRNA Gene Amplification and Sequencing
2.4. Taxonomy Quantification Using 16S rRNA Gene Sequences and Statistical Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Acknowledgments
Conflicts of Interest
References
- Yachida, S.; Mizutani, S.; Shiroma, H.; Shiba, S.; Nakajima, T.; Sakamoto, T.; Watanabe, H.; Masuda, K.; Nishimoto, Y.; Kubo, M.; et al. Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer. Nat. Med. 2019, 25, 968–976. [Google Scholar] [CrossRef]
- Xavier, J.B.; Young, V.B.; Skufca, J.; Ginty, F.; Testerman, T.; Pearson, A.T.; Macklin, P.; Mitchell, A.; Shmulevich, I.; Xie, L.; et al. The Cancer Microbiome: Distinguishing Direct and Indirect Effects Requires a Systemic View. Trends Cancer 2020, 6, 192–204. [Google Scholar] [CrossRef]
- Routy, B.; Le Chatelier, E.; Derosa, L.; Duong, C.P.M.; Alou, M.T.; Daillère, R.; Fluckiger, A.; Messaoudene, M.; Rauber, C.; Roberti, M.P.; et al. Gut Microbiome Influences Efficacy of PD-1-Based Immunotherapy Against Epithelial Tumors. Science 2018, 359, 91–97. [Google Scholar] [CrossRef]
- Chiu, C.Y.; Miller, S.A. Clinical metagenomics. Nat. Rev. Genet. 2019, 20, 341–355. [Google Scholar] [CrossRef]
- Wu, Y.; Jiao, N.; Zhu, R.; Zhang, Y.; Wu, D.; Wang, A.J.; Fang, S.; Tao, L.; Li, Y.; Cheng, S.; et al. Identification of microbial markers across populations in early detection of colorectal cancer. Nat. Commun. 2021, 24, 3063. [Google Scholar] [CrossRef]
- Cheng, T.Y.; Cramb, S.M.; Baade, P.D.; Youlden, D.R.; Nwogu, C.; Reid, M.E. The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics. J. Thorac. Oncol. 2016, 11, 1653–1671. [Google Scholar] [CrossRef]
- Tsao, M.S.; Yoon, J.Y. The eighth TNM classification for lung cancer-What is next? Lung Cancer 2018, 121, 97–98. [Google Scholar] [CrossRef]
- Molina, J.R.; Yang, P.; Cassivi, S.D.; Schild, S.E.; Adjei, A.A. Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin. Proc. 2008, 83, 584–594. [Google Scholar] [CrossRef]
- Man, J.; Zhang, X.; Dong, H.; Li, S.; Yu, X.; Meng, L.; Gu, X.; Yan, H.; Cui, J.; Lai, Y. Screening and identification of key biomarkers in lung squamous cell carcinoma by bioinformatics analysis. Oncol. Lett. 2019, 18, 5185–5196. [Google Scholar] [CrossRef]
- Mao, Q.; Jiang, F.; Yin, R.; Wang, J.; Xia, W.; Dong, G.; Ma, W.; Yang, Y.; Xu, L.; Hu, J. Interplay between the lung microbiome and lung cancer. Cancer Lett. 2018, 415, 40–48. [Google Scholar] [CrossRef]
- Maddi, A.; Sabharwal, A.; Violante, T.; Manuballa, S.; Genco, R.; Patnaik, S.; Yendamuri, S. The microbiome and lung cancer. J. Thorac. Dis. 2019, 11, 280–291. [Google Scholar] [CrossRef] [PubMed]
- Hasegawa, A.; Sato, T.; Hoshikawa, Y.; Ishida, N.; Tanda, N.; Kawamura, Y.; Kondo, T.; Takahashi, N. Detection and identification of oral anaerobes in intraoperative bronchial fluids of patients with pulmonary carcinoma. Microbiol. Immunol. 2014, 58, 375–381. [Google Scholar] [CrossRef] [PubMed]
- Lee, S.H.; Sung, J.Y.; Yong, D.; Chun, J.; Kim, S.Y.; Song, J.H.; Chung, K.S.; Kim, E.Y.; Jung, J.Y.; Kang, Y.A.; et al. Characterization of microbiome in bronchoalveolar lavage fluid of patients with lung cancer comparing with benign mass like lesions. Lung Cancer 2016, 102, 89–95. [Google Scholar] [CrossRef] [PubMed]
- Liu, H.X.; Tao, L.L.; Zhang, J.; Zhu, Y.G.; Zheng, Y.; Liu, D.; Zhou, M.; Ke, H.; Shi, M.M.; Qu, J.M. Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects. Int. J. Cancer 2018, 142, 769–778. [Google Scholar] [CrossRef] [PubMed]
- Tsay, J.J.; Wu, B.G.; Badri, M.H.; Clemente, J.C.; Shen, N.; Meyn, P.; Li, Y.; Yie, T.A.; Lhakhang, T.; Olsen, E.; et al. Airway Microbiota Is Associated with Upregulation of the PI3K Pathway in Lung Cancer. Am. J. Respir. Crit. Care. Med. 2018, 198, 1188–1198. [Google Scholar] [CrossRef]
- Peters, B.A.; Hayes, R.B.; Goparaju, C.; Reid, C.; Pass, H.I.; Ahn, J. The microbiome in lung cancer tissue and recurrence-free survival. Cancer Epidemiol. Biomark. Prev. 2019, 28, 731–740. [Google Scholar] [CrossRef]
- Zhang, W.; Luo, J.; Dong, X.; Zhao, S.; Hao, Y.; Peng, C.; Shi, H.; Zhou, Y.; Shan, L.; Sun, Q.; et al. Salivary Microbial Dysbiosis is Associated with Systemic Inflammatory Markers and Predicted Oral Metabolites in Non-Small Cell Lung Cancer Patients. J. Cancer 2019, 10, 1651–1662. [Google Scholar] [CrossRef]
- Wang, K.; Huang, Y.; Zhang, Z.; Liao, J.; Ding, Y.; Fang, X.; Liu, L.; Luo, J.; Kong, J. A preliminary study of microbiota diversity in saliva and bronchoalveolar lavage fluid from patients with primary bronchogenic carcinoma. Med. Sci. Monit. 2019, 25, 2819–2834. [Google Scholar] [CrossRef]
- Cheng, C.; Wang, Z.; Wang, J.; Ding, C.; Sun, C.; Liu, P.; Xu, X.; Liu, Y.; Chen, B.; Gu, B. Characterization of the lung microbiome and exploration of potential bacterial biomarkers for lung cancer. Transl. Lung. Cancer Res. 2020, 9, 693–704. [Google Scholar] [CrossRef]
- Zhuo, M.; An, T.; Zhang, C.; Wang, Z. Characterization of Microbiota in Cancerous Lung and the Contralateral Non-Cancerous Lung within Lung Cancer Patients. Front. Oncol. 2020, 10, 1584. [Google Scholar] [CrossRef]
- Hosgood, H.D., 3rd; Sapkota, A.R.; Rothman, N.; Rohan, T.; Hu, W.; Xu, J.; Vermeulen, R.; He, X.; White, J.R.; Wu, G.; et al. The potential role of lung microbiota in lung cancer attributed to household coal burning exposures. Environ. Mol. Mutagen. 2014, 55, 643–651. [Google Scholar] [CrossRef] [PubMed]
- Cameron, S.J.S.; Lewis, K.E.; Huws, S.A.; Hegarty, M.J.; Lewis, P.D.; Pachebat, J.A.; Mur, L.A.J. A pilot study using metagenomic sequencing of the sputum microbiome suggests potential bacterial biomarkers for lung cancer. PLoS ONE 2017, 12, e0177062. [Google Scholar] [CrossRef] [PubMed]
- Hosgood, H.D., 3rd; Mongodin, E.F.; Wan, Y.; Hua, X.; Rothman, N.; Hu, W.; Vermeulen, R.; Seow, W.J.; Rohan, T.; Xu, J.; et al. The respiratory tract microbiome and its relationship to lung cancer and environmental exposures found in rural china. Environ. Mol. Mutagen. 2019, 60, 617–623. [Google Scholar] [CrossRef]
- Druzhinin, V.G.; Matskova, L.V.; Demenkov, P.S.; Baranova, E.D.; Volobaev, V.P.; Minina, V.I.; Apalko, S.V.; Churina, M.A.; Romanyuk, S.A.; Shcherbak, S.G.; et al. Taxonomic diversity of sputum microbiome in lung cancer patients and its relationship with chromosomal aberrations in blood lymphocytes. Sci. Rep. 2020, 10, 9681. [Google Scholar] [CrossRef]
- Ran, Z.; Liu, J.; Wang, F.; Xin, C.; Shen, X.; Zeng, S.; Song, Z.; Xiong, B. Analysis of Pulmonary Microbial Diversity in Patients with Advanced Lung Cancer Based on High-throughput Sequencing Technology. Zhongguo Fei Ai Za Zhi 2020, 23, 1031–1038. (In Chinese) [Google Scholar] [CrossRef]
- Herbst, R.S.; Heymach, J.V.; Lippman, S.M. Lung cancer. N. Engl. J. Med. 2008, 359, 1367–1380. [Google Scholar] [CrossRef] [PubMed]
- Goldstraw, P. New staging system: How does it affect our practice? J. Clin. Oncol. 2013, 31, 984–991. [Google Scholar] [CrossRef]
- Caporaso, J.G.; Kuczynski, J.; Stombaugh, J.; Bittinger, K.; Bushman, F.D.; Costello, E.K.; Fierer, N.; Peña, A.G.; Goodrich, J.K.; Gordon, J.I.; et al. QIIME allows analysis of high-throughput community sequencing data. Nat. Methods 2010, 7, 335–336. [Google Scholar] [CrossRef]
- Bolyen, E.; Rideout, J.R.; Dillon, M.R.; Bokulich, N.A.; Abnet, C.C.; Al-Ghalith, G.A.; Alexander, H.; Alm, E.J.; Arumugam, M.; Asnicar, F.; et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat. Biotechnol. 2019, 37, 852–857. [Google Scholar] [CrossRef]
- Sorenson, T. A method of establishing groups of equal amplitudes in plant sociology based on similarity of species content and its application to analyses of the vegetation on Danish Commons. Biol. Skri. 1948, 5, 1–34. [Google Scholar]
- Huang, D.; Su, X.; Yuan, M.; Zhang, S.; He, J.; Deng, Q.; Qiu, W.; Dong, H.; Cai, S. The characterization of lung microbiome in lung cancer patients with different clinicopathology. Am. J. Cancer Res. 2019, 9, 2047–2063. [Google Scholar] [PubMed]
- Sommariva, M.; Le Noci, V.; Bianchi, F.; Camelliti, S.; Balsari, A.; Tagliabue, E.; Sfondrini, L. The lung microbiota: Role in maintaining pulmonary immune homeostasis and its implications in cancer development and therapy. Cell Mol. Life Sci. 2020, 77, 2739–2749. [Google Scholar] [CrossRef] [PubMed]
- Greathouse, K.L.; White, J.R.; Vargas, A.J.; Bliskovsky, V.V.; Beck, J.A.; von Muhlinen, N.; Polley, E.C.; Bowman, E.D.; Khan, M.A.; Robles, A.I.; et al. Interaction between the microbiome and TP53 in human lung cancer. Genome Biol. 2018, 19, 123. [Google Scholar] [CrossRef] [PubMed]
- Xu, N.; Wang, L.; Li, C.; Ding, C.; Li, C.; Fan, W.; Cheng, C.; Gu, B. Microbiota dysbiosis in lung cancer: Evidence of association and potential mechanisms. Transl. Lung Cancer Res. 2020, 9, 1554–1568. [Google Scholar] [CrossRef]
- Segal, L.N.; Clemente, J.C.; Tsay, J.C.; Koralov, S.B.; Keller, B.C.; Wu, B.G.; Li, Y.; Shen, N.; Ghedin, E.; Morris, A.; et al. Enrichment of the lung microbiome with oral taxa is associated with lung inflammation of a Th17 phenotype. Nat. Microbiol. 2016, 1, 16031. [Google Scholar] [CrossRef]
- Leng, Q.; Holden, V.K.; Deepak, J.; Todd, N.W.; Jiang, F. Microbiota Biomarkers for Lung Cancer. Diagnostics 2021, 11, 407. [Google Scholar] [CrossRef]
- Bello, S.; Vengoechea, J.J.; Ponce-Alonso, M.; Figueredo, A.L.; Mincholé, E.; Rezusta, A.; Gambó, P.; Pastor, J.M.; Galeano, J.; Del Campo, R. Core Microbiota in Central Lung Cancer with Streptococcal Enrichment as a Possible Diagnostic Marker. Arch. Bronconeumol. 2021, 57, 681–689. [Google Scholar] [CrossRef]
- Morris, A.; Beck, J.M.; Schloss, P.D.; Campbell, T.B.; Crothers, K.; Curtis, J.L.; Flores, S.C.; Fontenot, A.P.; Ghedin, E.; Huang, L.; et al. Microbiome Project. Comparison of the respiratory microbiome in healthy nonsmokers and smokers. Am. J. Respir. Crit. Care. Med. 2013, 187, 1067–1075. [Google Scholar] [CrossRef]
- Haldar, K.; George, L.; Wang, Z.; Mistry, V.; Ramsheh, M.Y.; Free, R.C.; John, C.; Reeve, N.F.; Miller, B.E.; Tal-Singer, R.; et al. The sputum microbiome is distinct between COPD and health, independent of smoking history. Respir. Res. 2020, 21, 183. [Google Scholar] [CrossRef]
- Kumar, R.; Herold, J.L.; Schady, D.; Davis, J.; Kopetz, S.; Martinez-Moczygemba, M.; Murray, B.E.; Han, F.; Li, Y.; Callaway, E.; et al. Streptococcus gallolyticus subsp. gallolyticus promotes colorectal tumor development. PLoS Pathog. 2017, 13, e1006440. [Google Scholar] [CrossRef]
- Manning, S.D. Molecular epidemiology of Streptococcus agalactiae (group B Streptococcus). Front. Biosci. 2003, 8, s1–s18. [Google Scholar] [CrossRef] [PubMed]
- Furfaro, L.L.; Chang, B.J.; Payne, M.S. Perinatal Streptococcus agalactiae Epidemiology and Surveillance Targets. Clin. Microbial. Rev. 2018, 31, e00049-18. [Google Scholar] [CrossRef] [PubMed]
- Pimentel, B.A.; Martins, C.A.; Mendonça, J.C.; Miranda, P.S.; Sanches, G.F.; Mattos-Guaraldi, A.L.; Nagao, P.E. Streptococcus agalactiae infection in cancer patients: A five-year study. Eur. J. Clin. Microbiol. Infect. Dis. 2016, 35, 927–933. [Google Scholar] [CrossRef] [PubMed]
- Phares, C.R.; Lynfield, R.; Farley, M.M.; Mohle-Boetani, J.; Harrison, L.H.; Petit, S.; Craig, A.S.; Schaffner, W.; Zansky, S.M.; Gershman, K.; et al. Active Bacterial Core surveillance/Emerging Infections Program Network. Epidemiology of invasive group B streptococcal disease in the United States, 1999–2005. JAMA 2008, 299, 2056–2065. [Google Scholar] [CrossRef] [PubMed]
- Farley, M.M.; Harvey, R.C.; Stull, T.; Smith, J.D.; Schuchat, A.; Wenger, J.D.; Stephens, D.S. A population-based assessment of invasive disease due to group B Streptococcus in nonpregnant adults. N. Engl. J. Med. 1993, 328, 1807–1811. [Google Scholar] [CrossRef]
- Sharma, P.; Lata, H.; Arya, D.K.; Kashyap, A.K.; Kumar, H.; Dua, M.; Ali, A.; Johri, A.K. Role of pilus proteins in adherence and invasion of Streptococcus agalactiae to the lung and cervical epithelial cells. J. Biol. Chem. 2013, 288, 4023–4034. [Google Scholar] [CrossRef]
- Da Costa, A.F.E.; Moraes, J.A.; De Oliveira, J.S.S.; Dos Santos, M.H.B.; Santos, G.D.S.; Barja-Fidalgo, C.; Mattos-Guaraldi, A.L.; Nagao, P.E. Reactive oxygen species involved in apoptosis induction of human respiratory epithelial (A549) cells by Streptococcus agalactiae. Microbiology 2013, 162, 94–99. [Google Scholar] [CrossRef]
- Oliveira, J.S.S.; Santos, G.D.S.; Moraes, J.A.; Saliba, A.M.; Barja-Fidalgo, T.C.; Mattos-Guaraldi, A.L.; Nagao, P.E. Reactive oxygen species generation mediated by NADPH oxidase and PI3K/Akt pathways contribute to invasion of Streptococcus agalactiae in human endothelial cells. Mem. Inst. Oswaldo Cruz. 2018, 113, e140421. [Google Scholar] [CrossRef] [Green Version]
Variables | Squamous Cell Lung Carcinoma, n = 40 | Healthy Kemerovo Residents (Control), n = 40 |
---|---|---|
Age (years) (mean ± SD) | 59.9 ± 6.9 * | 54.0 ± 5.3 |
Living environment (%): | ||
City | 67.0 | 85.0 |
Village | 33.0 | 15.0 |
Occupational exposure (%): | ||
Yes | 45.0 | 0 |
No | 65.0 | 100 |
Smoking status (%): | ||
Non-smokers | 25.0 | 45.0 |
Smokers | 75.0 | 55.0 |
Smoking pack-years (mean ± SD) | 37.13 ± 12.7 | 32.91 ± 12.62 |
Alcohol status (%): | ||
Non-drinker | 25.0 | 10.0 |
Rare drinker (1–2 times per month) | 52.0 | 45.0 |
Medium drinker (1–2 times a week) | 23.0 | 45.0 |
Diet (%): | ||
Vegetarian | 0 | 0 |
Non-vegetarian | 100 | 100 |
Family cancer history (%): | ||
Yes | 28.0 | 40.0 |
No | 72.2 | 60.0 |
Chronic diseases (%): | ||
Heart and vessels | 90.0 | 22.5 |
Bronchitis | 32.5 | 7.5 |
COPD | 45.0 | 0 |
Stomach (gastritis, ulcer) | 17.5 | 15.0 |
Diabetes | 0 | 2.5 |
Obesity | 20.0 | 0 |
TNM # (%): | - | |
I, II | 45.0 | |
III, IV | 55.0 | |
Distant metastasis (%): | - | |
Yes | 5.0 | |
No | 95.0 | |
Tumor localization (%): | - | |
Central lung cancer | 30 | |
Peripheral lung cancer | 42.5 | |
Mixed lung cancer | 7.5 | |
Bronchial cancer | 20 |
Genus | Squamous Cell Lung Cancer, % (n = 40) | Controls, % (n = 40) | p * |
---|---|---|---|
Streptococcus | 36.26 ± 20.02 | 18.93 ± 10.43 | 0.00001 |
Prevotella (f.Prevotellfceae) | 10.86 ± 7.03 | 17.89 ± 7.37 | 0.00003 |
Veillonella | 6.6 ± 7.45 | 11.17 ± 6.22 | 0.00009 |
Anaerosinus | 6.57 ± 7.69 | 10.91 ± 6.33 | 0.0003 |
Gemella | 3.6 ± 2.89 | 2.01 ± 2.01 | 0.004 |
Bacillus | 3.55 ± 2.96 | 1.84 ± 1.93 | 0.003 |
Haemophilus | 2.2 ± 10.32 | 0.13 ± 0.4 | 0.003 |
Selenomonas | 1.68 ± 2.82 | 4.36 ± 3.49 | 0.00003 |
Megasphaera | 1.38 ± 2.91 | 2.44 ± 2.27 | 0.005 |
Streptobacillus | 1.14 ± 1.46 | 2.85 ± 2.69 | 0.002 |
Atopobium | 1.22 ± 1.79 | 1.66 ± 1.47 | 0.02 |
Leptotrichia | 1.13 ± 1.35 | 2.63 ± 2.49 | 0.008 |
Treponema | 0.43 ± 0.76 | 0.73 ± 1.01 | 0.002 |
Lachnoanaerobaculum | 0.39 ± 0.53 | 0.65 ± 0.65 | 0.03 |
Porphiromonas | 0.35 ± 0.75 | 0.93 ± 1.3 | 0.002 |
Parvimonas | 0.42 ± 0.83 | 0.83 ± 1.06 | 0.002 |
Stomatobaculum | 0.39 ± 0.42 | 0.9 ± 0.81 | 0.003 |
Vestibaculum | 0.35 ± 1.1 | 0.86 ± 1.45 | 0.005 |
Catonella | 0.09 ± 0.32 | 0.14 ± 0.25 | 0.03 |
Filifactor | 0.06 ± 0.16 | 0.21 ± 0.33 | 0.003 |
Mycoplasma | 0.04 ± 0.09 | 0.28 ± 0.72 | 0.02 |
Moriella | 0.05 ± 0.18 | 0.36 ± 0.83 | 0.02 |
Cardiobacterium | 0.02 ± 0.1 | 0.04 ± 0.1 | 0.03 |
Species | Squamous Cell Lung Cancer, n = 40 | Controls, n = 40 | p * |
---|---|---|---|
Streptococcus agalactiae | 35.47 ± 20.19 | 19.11 ± 10.06 | 0.00004 |
Anaerosinus glycerini | 4.8 ± 6.31 | 10.19 ± 6.81 | 0.0003 |
Selenomonas bovis | 1.44 ± 2.62 | 4.36 ± 4.46 | 0.00001 |
Prevotella histicola F0411 | 1.42 ± 2.27 | 2.84 ± 3.2 | 0.02 |
Atopobium rimae | 1.29 ± 1.77 | 1.68 ± 1.46 | 0.03 |
Megasphaera Micronuciformis | 1.23 ± 2.88 | 2.39 ± 2.34 | 0.001 |
Lachnoanaerobaculum orale | 0.36 ± 0.5 | 0.69 ± 0.64 | 0.01 |
Vestibaculum illigatum | 0.29 ± 0.98 | 0.91 ± 1.46 | 0.003 |
Rothia dentocariosa ATCC 17931 | 0.23 ± 0.6 | 0.53 ± 0.8 | 0.02 |
Prevotella sp.oral clone DO014 | 0.16 ± 0.44 | 0.52 ± 0.6 | 0.0007 |
Porphyromonas endodontalis | 0.14 ± 0.34 | 0.93 ± 1.3 | 0.003 |
Prevotella intermedia | 0.14 ± 0.34 | 0.47 ± 0.96 | 0.04 |
Moryella indoligenes | 0.06 ± 0.19 | 0.4 ± 0.895 | 0.03 |
Prevotella nigrescens | 0.09 ± 0.22 | 0.43 ± 1.11 | 0.02 |
Oribacterium Sinus | 0.07 ± 0.22 | 0.26 ± 0.51 | 0.03 |
Leptotrichia sp. oral clone EI013 | 0.06 ± 0.18 | 0.24 ± 0.54 | 0.0008 |
Filifactor alocis ATCC 35896 | 0.06 ± 0.16 | 0.21 ± 0.33 | 0.007 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Baranova, E.; Druzhinin, V.; Matskova, L.; Demenkov, P.; Volobaev, V.; Minina, V.; Larionov, A.; Titov, V. Sputum Microbiome Composition in Patients with Squamous Cell Lung Carcinoma. Life 2022, 12, 1365. https://doi.org/10.3390/life12091365
Baranova E, Druzhinin V, Matskova L, Demenkov P, Volobaev V, Minina V, Larionov A, Titov V. Sputum Microbiome Composition in Patients with Squamous Cell Lung Carcinoma. Life. 2022; 12(9):1365. https://doi.org/10.3390/life12091365
Chicago/Turabian StyleBaranova, Elizaveta, Vladimir Druzhinin, Ludmila Matskova, Pavel Demenkov, Valentin Volobaev, Varvara Minina, Alexey Larionov, and Victor Titov. 2022. "Sputum Microbiome Composition in Patients with Squamous Cell Lung Carcinoma" Life 12, no. 9: 1365. https://doi.org/10.3390/life12091365